Cargando…

Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment

PURPOSE: Our purpose was to compare the impact in diabetic macula edema (DME) of two intravitreal drugs (0.5 mg ranibizumab vs. 8 mg triamcinolone) on changes in retinal morphology in spectral-domain optical coherence tomography (SD OCT) images, color fundus photography (CF) and fluorescein angiogra...

Descripción completa

Detalles Bibliográficos
Autores principales: Karst, Sonja G., Lammer, Jan, Mitsch, Christoph, Schober, Manuela, Mehta, Janhvi, Scholda, Christoph, Kundi, Michael, Kriechbaum, Katharina, Schmidt-Erfurth, Ursula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748439/
https://www.ncbi.nlm.nih.gov/pubmed/29080915
http://dx.doi.org/10.1007/s00417-017-3828-1
_version_ 1783289399464689664
author Karst, Sonja G.
Lammer, Jan
Mitsch, Christoph
Schober, Manuela
Mehta, Janhvi
Scholda, Christoph
Kundi, Michael
Kriechbaum, Katharina
Schmidt-Erfurth, Ursula
author_facet Karst, Sonja G.
Lammer, Jan
Mitsch, Christoph
Schober, Manuela
Mehta, Janhvi
Scholda, Christoph
Kundi, Michael
Kriechbaum, Katharina
Schmidt-Erfurth, Ursula
author_sort Karst, Sonja G.
collection PubMed
description PURPOSE: Our purpose was to compare the impact in diabetic macula edema (DME) of two intravitreal drugs (0.5 mg ranibizumab vs. 8 mg triamcinolone) on changes in retinal morphology in spectral-domain optical coherence tomography (SD OCT) images, color fundus photography (CF) and fluorescein angiography (FA) images during a 1-year follow-up. METHODS: Post hoc analysis was conducted of morphologic characteristics in OCT, FA and CF images of eyes with a center involving DME that were included in a prospective double-masked randomized trial. Eligible patients were divided at random into two groups receiving either pro re nata treatment with 0.5 mg ranibizumab or 8 mg triamcinolone after a fixed loading dose. OCT and CF images were acquired at monthly visits and FA images every three months. RESULTS: Twenty-five eyes of 25 patients (ranibizumab: n = 10; triamcinolone: n = 15) were included in this study. Patients treated with ranibizumab showed better visual acuity results after 12 months than patients receiving triamcinolone (p = 0.015) although edema reduction was similar (p = 0.426) in both groups. The initial effect on macular edema shedding after a single ranibizumab injection could be amplified with the following two injections of the loading dose. After a single injection of triamcinolone the beneficial initial effect on the macula edema faded within 3 months. Subretinal fluid and INL cystoid spaces diminished early in the course of treatment while fluid accumulation in the ONL seemed to be more persistent in both treatment arms. In FA, the area of leakage diminished significantly in both treatment arms. After repeated injections the morphologic OCT and FA characteristics of the treatment arms converged. CONCLUSIONS: Despite the higher dosage of triamcinolone, both therapies were safe and effective for treating diabetic macular edema. Fluid accumulation in the INL and subretinal space was more responsive to therapy than fluid accumulation in the ONL. Clinicaltrials.gov: NCT00682539.
format Online
Article
Text
id pubmed-5748439
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-57484392018-01-19 Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment Karst, Sonja G. Lammer, Jan Mitsch, Christoph Schober, Manuela Mehta, Janhvi Scholda, Christoph Kundi, Michael Kriechbaum, Katharina Schmidt-Erfurth, Ursula Graefes Arch Clin Exp Ophthalmol Retinal Disorders PURPOSE: Our purpose was to compare the impact in diabetic macula edema (DME) of two intravitreal drugs (0.5 mg ranibizumab vs. 8 mg triamcinolone) on changes in retinal morphology in spectral-domain optical coherence tomography (SD OCT) images, color fundus photography (CF) and fluorescein angiography (FA) images during a 1-year follow-up. METHODS: Post hoc analysis was conducted of morphologic characteristics in OCT, FA and CF images of eyes with a center involving DME that were included in a prospective double-masked randomized trial. Eligible patients were divided at random into two groups receiving either pro re nata treatment with 0.5 mg ranibizumab or 8 mg triamcinolone after a fixed loading dose. OCT and CF images were acquired at monthly visits and FA images every three months. RESULTS: Twenty-five eyes of 25 patients (ranibizumab: n = 10; triamcinolone: n = 15) were included in this study. Patients treated with ranibizumab showed better visual acuity results after 12 months than patients receiving triamcinolone (p = 0.015) although edema reduction was similar (p = 0.426) in both groups. The initial effect on macular edema shedding after a single ranibizumab injection could be amplified with the following two injections of the loading dose. After a single injection of triamcinolone the beneficial initial effect on the macula edema faded within 3 months. Subretinal fluid and INL cystoid spaces diminished early in the course of treatment while fluid accumulation in the ONL seemed to be more persistent in both treatment arms. In FA, the area of leakage diminished significantly in both treatment arms. After repeated injections the morphologic OCT and FA characteristics of the treatment arms converged. CONCLUSIONS: Despite the higher dosage of triamcinolone, both therapies were safe and effective for treating diabetic macular edema. Fluid accumulation in the INL and subretinal space was more responsive to therapy than fluid accumulation in the ONL. Clinicaltrials.gov: NCT00682539. Springer Berlin Heidelberg 2017-10-28 2018 /pmc/articles/PMC5748439/ /pubmed/29080915 http://dx.doi.org/10.1007/s00417-017-3828-1 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Retinal Disorders
Karst, Sonja G.
Lammer, Jan
Mitsch, Christoph
Schober, Manuela
Mehta, Janhvi
Scholda, Christoph
Kundi, Michael
Kriechbaum, Katharina
Schmidt-Erfurth, Ursula
Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment
title Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment
title_full Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment
title_fullStr Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment
title_full_unstemmed Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment
title_short Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment
title_sort detailed analysis of retinal morphology in patients with diabetic macular edema (dme) randomized to ranibizumab or triamcinolone treatment
topic Retinal Disorders
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748439/
https://www.ncbi.nlm.nih.gov/pubmed/29080915
http://dx.doi.org/10.1007/s00417-017-3828-1
work_keys_str_mv AT karstsonjag detailedanalysisofretinalmorphologyinpatientswithdiabeticmacularedemadmerandomizedtoranibizumabortriamcinolonetreatment
AT lammerjan detailedanalysisofretinalmorphologyinpatientswithdiabeticmacularedemadmerandomizedtoranibizumabortriamcinolonetreatment
AT mitschchristoph detailedanalysisofretinalmorphologyinpatientswithdiabeticmacularedemadmerandomizedtoranibizumabortriamcinolonetreatment
AT schobermanuela detailedanalysisofretinalmorphologyinpatientswithdiabeticmacularedemadmerandomizedtoranibizumabortriamcinolonetreatment
AT mehtajanhvi detailedanalysisofretinalmorphologyinpatientswithdiabeticmacularedemadmerandomizedtoranibizumabortriamcinolonetreatment
AT scholdachristoph detailedanalysisofretinalmorphologyinpatientswithdiabeticmacularedemadmerandomizedtoranibizumabortriamcinolonetreatment
AT kundimichael detailedanalysisofretinalmorphologyinpatientswithdiabeticmacularedemadmerandomizedtoranibizumabortriamcinolonetreatment
AT kriechbaumkatharina detailedanalysisofretinalmorphologyinpatientswithdiabeticmacularedemadmerandomizedtoranibizumabortriamcinolonetreatment
AT schmidterfurthursula detailedanalysisofretinalmorphologyinpatientswithdiabeticmacularedemadmerandomizedtoranibizumabortriamcinolonetreatment